Caricamento...
The Use of Exenatide in Islet Transplant Recipients with Chronic Allograft Dysfunction: Safety, Efficacy and Metabolic Effects
BACKGROUND: A current limitation of islet transplantation is reduced long term graft function. The glucagon like peptide-1 (GLP-1) receptor agonist, exenatide (Byetta(®), Amylin Pharmaceuticals, CA) has properties that could improve existing islet function, prevent further loss of islet mass and pos...
Salvato in:
| Autori principali: | , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2008
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2772201/ https://ncbi.nlm.nih.gov/pubmed/18622276 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TP.0b013e31817c4ab3 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|